| 78.63 0.75 (0.96%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 93.88 | 1-year : | 109.65 |
| Resists | First : | 80.37 | Second : | 93.88 |
| Pivot price | 77.4 |
|||
| Supports | First : | 74.63 |
Second : | 71.08 |
| MAs | MA(5) : | 78.26 |
MA(20) : | 76.52 |
| MA(100) : | 75.46 |
MA(250) : | 73.4  |
|
| MACD | MACD : | 1.2 |
Signal : | 1 |
| %K %D | K(14,3) : | 71 |
D(3) : | 71 |
| RSI | RSI(14): 65.5 |
|||
| 52-week | High : | 81 | Low : | 64.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HOLX ] has closed below upper band by 27.0%. Bollinger Bands are 35.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.47 - 79.86 | 79.86 - 80.19 |
| Low: | 76.77 - 77.21 | 77.21 - 77.6 |
| Close: | 77.96 - 78.65 | 78.65 - 79.25 |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Fri, 26 Jul 2024
Hologic Inc. stock rises Friday, still underperforms market - MarketWatch
Fri, 26 Jul 2024
Ameritas Investment Partners Inc. Reduces Stock Position in Hologic, Inc. (NASDAQ:HOLX) - Defense World
Fri, 26 Jul 2024
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions - Yahoo Finance
Thu, 25 Jul 2024
Hologic Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Thu, 25 Jul 2024
Gear Up for Hologic (HOLX) Q3 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
Thu, 25 Jul 2024
Hologic Completes Acquisition of Endomagnetics Ltd - Hologic, Inc. - Investor Relations
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 233 (M) |
| Shares Float | 230 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 98.8 (%) |
| Shares Short | 4,730 (K) |
| Shares Short P.Month | 5,080 (K) |
| EPS | 1.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.76 |
| Profit Margin | 11.7 % |
| Operating Margin | 23.8 % |
| Return on Assets (ttm) | 6.2 % |
| Return on Equity (ttm) | 9.1 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 16.96 |
| EBITDA (p.s.) | 5.22 |
| Qtrly Earnings Growth | -17.3 % |
| Operating Cash Flow | 1,100 (M) |
| Levered Free Cash Flow | 737 (M) |
| PE Ratio | 40.53 |
| PEG Ratio | 2.5 |
| Price to Book value | 3.78 |
| Price to Sales | 4.63 |
| Price to Cash Flow | 16.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|